Lung cancer study explores new drug combo after treatment fails
NCT ID NCT00596648
First seen Jan 20, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This study tested a drug called cabozantinib, given alone or with another drug called erlotinib, in 92 adults with advanced non-small cell lung cancer. Participants had already tried erlotinib and their cancer had gotten worse. The goal was to find a safe dose and see if the combination could shrink tumors. The study was completed, and results help guide future treatment options for this type of lung cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Georgetown University/Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
Katmai Oncology Group
Anchorage, Alaska, 99508, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Park Nicollet Institute
Saint Louis Park, Minnesota, 55416, United States
-
Stanford University Medical Center
Palo Alto, California, 94305, United States
-
Summit Medical Group
Berkeley Heights, New Jersey, 07922, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
University of California, Davis
Sacramento, California, 95817, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Washington/ Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Yale University School of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.